← MeiraGTx Holdings plc (MGTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MeiraGTx Holdings plc (MGTX)
Biological Products, (No Diagnostic Substances) · market cap $1.1B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
MeiraGTx Holdings plc (MGTX) is a clinical-stage gene therapy company with a market cap of ~$1.15B developing AAV-based ocular gene therapies. Its lead assets target achromatopsia (AAV-CNGA3 and AAV-CNGB3, both Phase 2) and Leber Congenital Amaurosis (AAV-RPE65, Phase 2). With $71.5M in cash, an R&D burn of ~$130M in 2025, and no disclosed runway figure, near-term financing risk is a central concern.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| adeno-associated virus vector AAV- CNGA3 | Phase 2 | Achromatopsia |
| AAV - CNGB3 | Phase 2 | Achromatopsia |
| AAV RPE65 | Phase 2 | Leber Congenital Amaurosis |
Price & technical context
3-month
-23.4%
6-month
+17.3%
12-month
+29.5%
52-wk range
$6.99–$14.97
vs 50-day MA
-17.4%
vs 200-day MA
+5.7%
Realized vol
59.1%
Max drawdown
-43.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MGTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.